Altimmune announced that its pemvidutide Phase 2b trial data for metabolic dysfunction-associated steatohepatitis (MASH) will be presented at the EASL Congress 2026 in Barcelona. The 48-week trial results, recognized as "Best of EASL 2026," show promising efficacy and safety, including fibrosis regression and cardiovascular benefits. These findings support pemvidutide's potential as a treatment for serious liver diseases, with ongoing trials for related conditions. The presentations include oral and poster sessions highlighting detailed analyses of liver inflammation, fibrosis, and cardiovascular risk factors.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Meta Platforms has been upgraded to a buy rating due to its new cloud business, which is expected to stabilize cash flow and improve profitability. Despite heavy capital expenditures, Meta maintains strong free cash flow margins and operational effic...
Bitcoin Treasury Capital, a Stockholm-based firm, has received approval to issue 195,078 Class A preferred shares on the Spotlight Stock Market, starting July 20, 2026. These shares, priced at SEK 120 each, offer a 10% annual dividend backed entirely...
Willow Tree Research initiates coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, viewing the recent stock price decline as an overreaction. The company’s drug AMVUTTRA holds a near-term commercial monopoly in TTR silencing, with st...
